دورية أكاديمية
Potential Strategies to Improve the Effectiveness of Drug Therapy by Changing Factors Related to Tumor Microenvironment.
| العنوان: | Potential Strategies to Improve the Effectiveness of Drug Therapy by Changing Factors Related to Tumor Microenvironment. |
|---|---|
| المؤلفون: | Cao D; Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China., Naiyila X; Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.; West China School of Medicine, Sichuan University, Chengdu, China., Li J; Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.; West China School of Medicine, Sichuan University, Chengdu, China., Huang Y; Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.; West China School of Medicine, Sichuan University, Chengdu, China., Chen Z; Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.; West China School of Medicine, Sichuan University, Chengdu, China., Chen B; Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.; West China School of Medicine, Sichuan University, Chengdu, China., Li J; Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China.; West China School of Medicine, Sichuan University, Chengdu, China., Guo J; Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China., Dong Q; Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China., Ai J; Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China., Yang L; Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China., Liu L; Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China., Wei Q; Department of Urology/Institute of Urology, West China Hospital, Sichuan University, Chengdu, China. |
| المصدر: | Frontiers in cell and developmental biology [Front Cell Dev Biol] 2021 Aug 10; Vol. 9, pp. 705280. Date of Electronic Publication: 2021 Aug 10 (Print Publication: 2021). |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Frontiers Media S.A Country of Publication: Switzerland NLM ID: 101630250 Publication Model: eCollection Cited Medium: Print ISSN: 2296-634X (Print) Linking ISSN: 2296634X NLM ISO Abbreviation: Front Cell Dev Biol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: Lausanne : Frontiers Media S.A., [2013]- |
| مستخلص: | A tumor microenvironment (TME) is composed of various cell types and extracellular components. It contains tumor cells and is nourished by a network of blood vessels. The TME not only plays a significant role in the occurrence, development, and metastasis of tumors but also has a far-reaching impact on the effect of therapeutics. Continuous interaction between tumor cells and the environment, which is mediated by their environment, may lead to drug resistance. In this review, we focus on the key cellular components of the TME and the potential strategies to improve the effectiveness of drug therapy by changing their related factors. Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2021 Cao, Naiyila, Li, Huang, Chen, Chen, Li, Guo, Dong, Ai, Yang, Liu and Wei.) |
| References: | Nat Rev Clin Oncol. 2017 Jul;14(7):399-416. (PMID: 28117416) Eur J Immunol. 2012 Aug;42(8):2060-72. (PMID: 22653638) Stem Cells Int. 2017;2017:3714190. (PMID: 28337221) Oncogene. 2014 May 8;33(19):2423-31. (PMID: 23728338) Cell Mol Biol (Noisy-le-grand). 2017 Oct 31;63(10):131-136. (PMID: 29096753) Int J Cancer. 2009 Nov 15;125(10):2296-306. (PMID: 19610062) Pathol Res Pract. 2020 May;216(5):152915. (PMID: 32146002) Cancer Res. 2006 Jan 15;66(2):1123-31. (PMID: 16424049) J Immunother Cancer. 2018 Nov 16;6(1):119. (PMID: 30446007) Mol Cancer. 2020 Feb 27;19(1):43. (PMID: 32106859) J Exp Med. 2006 Nov 27;203(12):2691-702. (PMID: 17101732) Cancer Res. 2014 Sep 15;74(18):5057-69. (PMID: 25082815) Curr Opin Hematol. 2006 May;13(3):175-81. (PMID: 16567962) Cell. 2005 May 6;121(3):335-48. (PMID: 15882617) Oncoimmunology. 2015 Dec 10;5(3):e1089381. (PMID: 27141346) Nature. 2012 Jul 26;487(7408):500-4. (PMID: 22763439) Cytokine Growth Factor Rev. 2014 Aug;25(4):423-35. (PMID: 25156420) J Leukoc Biol. 2018 Mar;103(3):545-558. (PMID: 29345363) J Exp Med. 2013 Jun 3;210(6):1137-51. (PMID: 23712428) Proc Natl Acad Sci U S A. 2013 Dec 10;110(50):20212-7. (PMID: 24277834) J Intern Med. 2013 Feb;273(2):114-27. (PMID: 23216836) PLoS One. 2012;7(2):e30563. (PMID: 22363446) J Exp Med. 2013 Jun 3;210(6):1125-35. (PMID: 23712432) Nat Rev Drug Discov. 2019 Feb;18(2):99-115. (PMID: 30470818) Curr Med Chem. 2019;26(17):3026-3041. (PMID: 28875842) Crit Rev Oncol Hematol. 2012 Jun;82(3):296-309. (PMID: 21798756) Cell. 2018 Nov 1;175(4):1014-1030.e19. (PMID: 30343900) Cell. 2010 Apr 2;141(1):52-67. (PMID: 20371345) Nat Rev Drug Discov. 2018 Dec;17(12):887-904. (PMID: 30361552) Cancer Lett. 2015 Mar 28;358(2):115-123. (PMID: 25444903) Cancer Res. 2014 Jun 1;74(11):2962-73. (PMID: 24638982) Biochem Biophys Res Commun. 2013 Aug 2;437(3):397-402. (PMID: 23831470) J Cell Physiol. 2019 Jun;234(6):8381-8395. (PMID: 30417375) Nat Rev Immunol. 2009 Mar;9(3):162-74. (PMID: 19197294) Expert Rev Anticancer Ther. 2011 Apr;11(4):621-30. (PMID: 21504328) Cancer Res. 2011 Dec 15;71(24):7463-70. (PMID: 22025564) Cancer Res. 2014 Jun 1;74(11):2999-3010. (PMID: 24710408) Int J Oncol. 2019 Oct;55(4):879-895. (PMID: 31485609) Cancer Cell. 2012 Jun 12;21(6):822-35. (PMID: 22698406) Nat Med. 1997 Jul;3(7):730-7. (PMID: 9212098) J Exp Clin Cancer Res. 2010 Jun 22;29:80. (PMID: 20569497) Biogerontology. 2018 Oct;19(5):325-339. (PMID: 29959657) Neuro Oncol. 2013 Aug;15(8):1079-87. (PMID: 23828240) Int J Cancer. 2011 Jul 1;129(1):225-32. (PMID: 20830712) Open Biol. 2020 Sep;10(9):200111. (PMID: 32931721) Oncol Rep. 2015 Jul;34(1):33-42. (PMID: 25997540) J Tissue Viability. 2011 Nov;20(4):108-20. (PMID: 19995679) Cancer Res. 2011 Apr 1;71(7):2664-74. (PMID: 21324923) Cancer Res. 2018 Jan 1;78(1):157-167. (PMID: 29089297) Oncol Rep. 2018 Sep;40(3):1666-1674. (PMID: 30015971) Annu Rev Immunol. 2013;31:51-72. (PMID: 23157435) Front Immunol. 2018 Mar 02;9:398. (PMID: 29552012) Am J Pathol. 2012 Dec;181(6):1895-9. (PMID: 23063657) Carcinogenesis. 2010 Jul;31(7):1175-84. (PMID: 19892798) Cancer Treat Rev. 2018 Jan;62:50-60. (PMID: 29169144) Cells. 2020 Jan 15;9(1):. (PMID: 31952344) Clin Cancer Res. 2017 Feb 15;23(4):876-884. (PMID: 27895033) J Clin Invest. 2019 Feb 1;129(2):631-646. (PMID: 30431439) J Pathol. 2016 Oct;240(2):211-23. (PMID: 27425378) Oncotarget. 2017 Feb 28;8(9):15744-15762. (PMID: 28178651) Curr Opin Pharmacol. 2017 Aug;35:40-47. (PMID: 28577499) J Surg Res. 2009 Aug;155(2):231-6. (PMID: 19482312) Nat Med. 2014 Jun;20(6):676-81. (PMID: 24859530) Nat Med. 2018 Feb;24(2):224-231. (PMID: 29334374) Curr Opin Cell Biol. 2010 Oct;22(5):697-706. (PMID: 20822891) Oncotarget. 2014 Apr 30;5(8):2208-20. (PMID: 24809734) Int J Cancer. 2018 Sep 1;143(5):1017-1028. (PMID: 29417588) J Cell Biochem. 2019 Mar;120(3):2782-2790. (PMID: 30321449) Adv Exp Med Biol. 2018;1060:99-114. (PMID: 30155624) Cell Stem Cell. 2018 Mar 1;22(3):454-467.e6. (PMID: 29337182) BMC Urol. 2014 Jan 28;14:12. (PMID: 24472670) Immunity. 2014 Jul 17;41(1):14-20. (PMID: 25035950) Front Immunol. 2018 Jun 11;9:1310. (PMID: 29942309) Sci Transl Med. 2014 May 21;6(237):237ra67. (PMID: 24848257) Nat Rev Cancer. 2016 Aug 23;16(9):582-98. (PMID: 27550820) Cancer Cell. 2012 Mar 20;21(3):283-96. (PMID: 22439924) Oncotarget. 2016 Sep 13;7(37):60230-60244. (PMID: 27517626) Cell. 2005 Feb 11;120(3):303-13. (PMID: 15707890) Cancer Lett. 2014 Oct 1;352(2):160-8. (PMID: 24892648) J Cell Mol Med. 2005 Oct-Dec;9(4):777-94. (PMID: 16364190) Annu Rev Med. 2015;66:97-110. (PMID: 25341012) Biomed Pharmacother. 2020 Nov;131:110740. (PMID: 32942159) Am J Cancer Res. 2018 Feb 01;8(2):302-316. (PMID: 29511600) Cancer Lett. 2020 Mar 31;473:62-73. (PMID: 31904479) Nat Commun. 2017 Feb 08;8:14293. (PMID: 28176769) Cell. 2014 Sep 25;159(1):80-93. (PMID: 25259922) Trends Immunol. 2016 Mar;37(3):208-220. (PMID: 26858199) Acta Pharmacol Sin. 2018 Apr;39(4):534-541. (PMID: 29542685) Oncogenesis. 2015 Nov 30;4:e177. (PMID: 26619402) Exp Cell Res. 2010 Oct 15;316(17):2713-22. (PMID: 20451516) Nat Immunol. 2018 Feb;19(2):108-119. (PMID: 29348500) Cancer Res. 2016 Jun 1;76(11):3156-65. (PMID: 27197152) Clin Cancer Res. 2010 Mar 15;16(6):1812-23. (PMID: 20215551) Cancer Res. 2014 Jan 1;74(1):153-161. (PMID: 24247719) Proc Natl Acad Sci U S A. 2011 Jul 26;108(30):12425-30. (PMID: 21746895) Oncol Lett. 2018 Jun;15(6):8681-8686. (PMID: 29805605) Int J Biol Sci. 2019 Mar 10;15(5):984-998. (PMID: 31182919) J Immunol. 2004 Jan 15;172(2):989-99. (PMID: 14707072) Biol Blood Marrow Transplant. 2018 Jan;24(1):32-42. (PMID: 28844945) Stem Cells. 2014 Jan;32(1):145-56. (PMID: 24395741) Life Sci. 2020 May 15;249:117534. (PMID: 32156548) Biochem Pharmacol. 2013 Apr 15;85(8):1033-41. (PMID: 23376122) Cancer Res. 2007 Aug 1;67(15):7477-86. (PMID: 17671218) Cell Metab. 2016 Nov 8;24(5):701-715. (PMID: 27773694) Cancers (Basel). 2012 Sep;4(3):618-57. (PMID: 22946011) Oncoimmunology. 2018 Mar 26;7(7):e1445452. (PMID: 29900055) Oncogene. 2016 Feb 18;35(7):816-26. (PMID: 25961926) Sci Immunol. 2016 Aug;1(2):. (PMID: 28417112) Cell Death Differ. 2014 Jan;21(1):15-25. (PMID: 23787994) Cancer Lett. 2017 Feb 28;387:61-68. (PMID: 26845449) Mediators Inflamm. 2016;2016:6058147. (PMID: 26966341) Exp Cell Res. 2019 Oct 1;383(1):111543. (PMID: 31374207) Oncogenesis. 2016 Aug 08;5(8):e250. (PMID: 27500388) Immunity. 2013 Sep 19;39(3):611-21. (PMID: 24012420) Oncogene. 2017 Feb 2;36(5):639-651. (PMID: 27345402) Nat Rev Cancer. 2002 Nov;2(11):826-35. (PMID: 12415253) J Mol Med (Berl). 2021 Jan;99(1):1-20. (PMID: 33025106) Oral Oncol. 2019 Jan;88:115-123. (PMID: 30616781) Nat Rev Immunol. 2012 Mar 22;12(4):253-68. (PMID: 22437938) |
| فهرسة مساهمة: | Keywords: cancer-associated fibroblasts; drug therapy; targeted therapy; tumor microenvironment; tumor-associated macrophages |
| تواريخ الأحداث: | Date Created: 20210827 Latest Revision: 20210828 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC8383319 |
| DOI: | 10.3389/fcell.2021.705280 |
| PMID: | 34447750 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2296-634X |
|---|---|
| DOI: | 10.3389/fcell.2021.705280 |